Publications citing the use of ProImmune productsHave you published a paper citing the use of ProImmune's products or services? If so, please send us a reprint, either as a PDF by e-mail to enquiries@proimmune.com, or by mail to ProImmune Limited, The Magdalen Centre, The Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA, UK. We will send you a bottle of Champagne to celebrate with! (Limited to 1 bottle per publication). |
Further publications: |
||||||||||||||||||||
Publications citing Pro5® MHC PentamersAutoimmunityMonti, P. et al. (2008) Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 118: 1806-1814 [PubMedID: 18431516] A*02:01/VMNILLQYV (GAD 65)A*02:01/GILGFVFTL (Flu-A MP)A*02:01/SLYNTVATL (HIV gag p17)Monti, P. et al. (2007). Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J. Immunol. 179: 5785-92. [PubMedID: 17947651]. A*02:01/VMNILLQYV (GAD 65)A*02:01/GILGFVFTL (Flu-A MP)A*02:01/SLYNTVATL (HIV gag p17)CancerAli, OA. et al. (2009) Infection-mimicking materials to program dendritic cells in situ. Nature Materials. 8: 151-158. [PubMedID: 19136947] H-2Kb/SVYDFFVWL (TRP2)Andersen, MH. et al. (2009). Identification of heme-oxygenase-1-specific regulatory CD8+T cells in cancer patients. J. Clin. Invest. 119: 2245-2256.[PubMedID: 19662679] A*02:01/QLFEELQEL (Heme -oxygenase-1)A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/ILKEPVHGV (HIV-1 pol)A*02:01/SLYNTVATL (HIV-1 gag)Ansen, S. et al. (2008). Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin-21. Clin. Cancer Res. 14: 6125-6136 [PubMedID: 18829491] A*02:01/ELAGIGILTV (MelanA/MART1)Bergant, M. et al.(2006). Preparation of native and amplified tumour RNA for dendritic cell transfection and generation of in vitro anti-tumour CTL responses. Immunobiol. 211: 179-189. [[PubMedID:16530085]. A*02:01/YLSGANLNL (CEA)Bolonaki, I. et al. (2007).Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 25: 2727-2734. [PubMedID: 17602077]. A*02:01/YLFFYRKSV (mTERT)A*02:01/SMNTVATL (HIV gag)Bracci, L. et al. (2008) Efficient stimulation of T cell responses by human IFN-a-induced dendritic cells does not require Toll-like receptor triggering. J Immunother. 31: 466-474. [PubMedID: 18463538] A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/GILGFVFTL (Inlfuenza MP)A*02:01/YLEYRQVPV (MAGE)Britten, CM. et al. (2009). Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the cancer vaccine consortium. Cancer Immunol, Immunother. 58: 1701-1713.[PubMedID: 19259668] A*02:01/GILGFVFTL (Influenza MP)A*02:01/ELAGIGILTV (MelanA/MART-1)Calderhead, DM. et al. (2008). Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother. 31: 731-741.[PubMedID: 18779746] A*02:01/ELAGIGILTV (MelanA/MART-1)Carnevale-Schianca, F. et al. (2006). Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 107: 3795-3803. [[PubMedID: 16403911] A*02:01/YLSGANLNL (CEA)A*02:01/NLVPMVATV(HCMV pp65)A*02:01/ELAGIGILTV (MelanA / MART-1) - Negative controlCasado, JG. et al. (2009) Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells. International Immunolgy. 21: 53-62.[PubMedID: 19050104] A*02:01/ELAGIGILTV (MelanA/MART-1)Cerullo et al. (2010) Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. Cancer Research 70: 4297-4309 [PubMedID: 20484030] A*02:01/LMLGEFLKL (Survivin)Chaise, C. et al. (2008). DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 112: 2956-2964.[PubMedID: 18502835] A*02:01/RMFPNAPYL (WT-1)A*02:01/CMTWNQMNL (WT-1)Chiang, CL-L. et al. (2008). Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin. Cancer Res. 14: 4898-4907 [PubMedID: 18676764] A*02:01/KIFGSLAFL (Her2/neu)Cohen, C.J. et al. (2007). Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67: 3898-3903.[[PubMedID: 17440104] A*02:01/LLGRNSFEV (p53)Cohen, C.J. et al.(2006). Enhanced antitumor activity of murine-human hybrid T cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.Cancer Res. 66: 8878-8886.[[PubMedID:16951205] A*02:01/LLGRNSFEV (p53)DeBenedette, MA. et al. (2008). Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J. Immunol. 181: 5296-5305 [PubMedID: 18832685] A*02:01/ELAGIGILTV (MelanA/MART-1)Domschke, C. et al. (2009). Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 69: 8420-8428. [PubMedID: 19843863] A*02:01/KIFGSLAFL (HER-2/neu)Escors, D. et al. (2008). Targeting dendritic cell signalling to regulate the response to immunisation. Blood. 111: 3050-61. [ PubMedID: 18180378] A*02:01/ELAGIGILTV (Melan-A/MART 1)Foster, et al. (2010). Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. epub ahead of print [PubMedID:20072155] A*02:01/ILSLELMKL (RHAMM)Freeman, JL. et al. (2007) CMRF-56 immunoselected blood dendritic cell preparations activated with GM-CSF induce potent antimyeloma cytotoxic T-cell responses. J Immunother. 30: 740-748. [PubMedID: 17893566] A*02:01/ELAGIGILTV (MelanA/MART-1)Geiger, R. et al. (2009). Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J. Exp. Med. 206: 1525-1534. [PubMedID: 19564353] A*02:01/ELAGIGILTV (MelanA/MART-1)Gritzapis, AD. et al.(2008). Identification of a novel immunogenic HLA-A*02:01-binding epitope of HER-2/neu with potent antitumor properties. J Immunol. 181: 146-154 PubMedID: 18566379] A*02:01/LIAHNQVRQV (Her-2(10))Hardy, MY. et al. (2009) NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunol. and Cell Biol. 87: 606-614 [PubMedID: 19546878] A*02:01/ELAGIGILTV (MelanA / MART-1)Harrop, R. et al. (2007). Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57: 977-986. [PubMedID: 18060404] A*02:01/RLARLALVL (5T4)A*02:01/FLTGNQALV (5T4)He, L. et al.(2005). A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J. Imm. Methods 304: 43-59. [[PubMedID: 16076473] A*02:01/SLYNTVATL (HIV-1 gag p17)A*02:01/YLSGANLNL(CEA)Himoudi, N. et al. (2008). MYCN as a target for cancer immunotherapy. Cancer Immunol. Immunother. 57: 693-700. [PubMedID: 18004567] A*02:01/VILKKATEYN (MYCN)Hirano, F. et al. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096. [PubMedID: 15705911] H-2Ld/LPYLGWLVF (Tumor antigen P815)Koido, S. et al. (2010). Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions. Clinical Immunology. 135, 384-400. [PubMedID: 20226739] A*02:01/RMFPNAPYL (WT1)A*24:02/RMFPNAPYL (WT1)A*02:01/YLSGANLNL (CEA)Koido, S. et al. (2008). In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J. Translational Medicine. 6: 51 [PubMedID: 18793383] A*02:01/RMFPNAPYL (WT1)A*02:01/YLSGANLNL (CEA)Koido, S. et al. (2007). Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J. Immunol. 179: 4874-83. [PubMedID: 17878387] A*02:01/YLSGANLNL (CEA)A*24:02/TYACFVSNL (CEA)Koido, S. et al. (2006). Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J. Immunol. 178: 613-622. [PubMedID: 17182602] A*02:01/STAPPVHNV (MUC-1)A*02:01/YLSGANLNL (CEA)A*24:02/TYACFVSNL (CEA)Koido, S. et al. (2005). Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11: 7891-7900. [PubMedID: 16278414] A*02:01/STAPPVHNV (MUC-1)A*02:01/YLSGANLNL (CEA)A*24:02/TYACFVSNL (CEA)Krambeck, A.E. et al.(2007). Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res. 13: 1749-1756. [ [PubMedID: 17363528] A*02:01/LMLGEFLKL (Survivin)Kuball, J. et al. (2007). Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109: 2331-2338. [PubMedID:17082316] Lopes, L. et al. (2008). Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J. Virol. 82: 86-95. [PubMedID: 17959670] A2Kb/SLLMWITQV (NY-ESO157-165)Mehrotra, S. et al. (2007). Inhibition of c-Jun N-terminal kinase (JNK) rescues influenza epitope-specific human cytolytic T lymphocytes (CTL) from activation-induced cell death (AICD). J. Leukoc. Biol. 81: 539-547. [[PubMedID: 17062604] A*02:01/GILGFVFTL (Influenza A MP)A*02:01/AAGIGILT (MelanA / MART-1)Milne, K. et al. (2008) Tumor-infiltrating T cells correlate with NY-ESO-1 specific autoantibodies in ovarian cancer. PLoS ONE 3: e3409 [PubMedID: 18923710] A*02:01/SLLMWITQV (NY-ESO-1)Moeller, I. et al. (2008) Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application.; J Immunother. 31:506-519.[PubMedID: 18463533] A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/ALQPGTALL (prostate stem cell antigen)A*02:01/KLVALGINAV (HCV NS3)Norell, H. et al. (2009). Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-127-35-Reactive T cells from activation-induced cell death. Cancer Res. 69: 6282-6289 [PubMedID: 19638595] A*02:01/ELAGIGILTV (MelanA/MART-1)Pavlenko, M. et al. (2005). Identification of an immunodominant H-2Db-restricted CTL epitope of human PSA. Prostate 64: 50-59. [PubMedID: 15651071] H-2Db/HCIRNKSVI (Prostate specific antigen)Peng, PD. et al. (2009). Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Therapy. 16: 1042-1049.[PubMedID: 19494842] A*02:01/LLGRNSFEV (p53)Prestwich, RJ. et al. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res. 14: 7358-7366[PubMedID: 19010851] A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/NegativeProvenzano, M. et al. (2006). Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*02:01+ BKV-seropositive donors. J. Transl. Med. 4: 47. [PubMedID: 17096832] A*02:01/ELAGIGILTV (MelanA/MART 1)A*02:01/VIFDFLHCI (BKV LTag)A*02:01/LLLIWFRPV (BKV LTag)Radford, KJ. et al. (2006). CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. J Immunother. 29: 596-605.[PubMedID: 17063122] A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/GILGFVFTL (Influenza MP)Rosenthal, R. et al. (2009). Differential responsiveness to IL-2, IL-7 and IL-15 common receptor gchain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother. 32: 252-261. [PubMedID: 19242375] A*02:01/NLVPMVATV (CMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/SLSAYIIRV (Vaccinia Virus H3L)A*02:01/KVDDTFYYV (Vaccinia Virus C7L)Sartorius, R. et al. (2008). The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. J. Immunol. 180: 3719-3728. [PubMedID: 18322177] A*02:01/FLWGPRALV (MAGE-A3)A*02:01/ILKEPVHGV (HIV-1 RT)Sebestyén, Z. et al. (2008). Human TCR that incorporate CD3c induce highly preferred pairing between TCRa and b chains following gene transfer. J. Immunol. 180: 7736-7746. [PubMedID: 18490778] A*02:01/YLEPGPVTA (gp100 (pmel17))A*01:01/EADPTGHSY (MAGE-A1)A*11:01/IVTDFVIK (EBV EBNA)A*02:01/ELAGIGILTV (MelanA / MART-1)Siegel, S. et al. (2006). Identification of HLA-A*02:01-presented T cell epitopes derived from the oncofetal antigen-immature Laminin receptor protein in patients with hematological malignancies. J. Immunol. 176: 6935-6944. [PubMedID:16709854] Soeda, A. et al (2009). Regular dose of Gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol. 39: 797-806. [PubMedID: 19797418] A*02:01/NLVPMVATV (CMV pp65)A*02:01/RMFPNAPYL (WT-1)A*24:02/CMTWNQMNL (WT-1)Stronen, E. et al (2009). Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumor cells. Scandinavian Journal of Immunology. 69: 319-328 [PubMedID: 19284496] A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/LLWAGALAM (CD33)A*02:01/VLWHWLLRT (CD19)A*02:01/NLVPMVATV (CMV pp65)Theoret, MR. et al. (2008). Relationship of p53 overexpression on cancers and recognition by anti-p53 TCR transduced T cells. Human Gene Therapy. epub ahead of print. [PubMedID: 18707199] A*02:01/LLGRNSFEV (p53)A*02:01/KTWGQYWQV (gp100)Wang, Z. et al. (2010) Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Chin Med J 123: 912-916 [PubMedID: 20497687] A*24:02/CMTWNQMNL (WT1 p235)Weber, G. et al. (2009). WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia. 23: 1634-1642 [PubMedID: 19357702] A*02:01/RMFPNAPYL (WT1 p126)A*02:01/CMTWNQMNL (WT1 p235)Wenandy, L. et al. (2008). The immunogenicity of the hTERT540-548 peptide in cancer. Clin. Cancer Res. 14: 4-7. [PubMedID: 18172245] A*02:01/ILAKFLHWL (hTERT)West, E. et al. (2009) Clinical grade OK432-activated dendritic cells. In vitro characterization and tracking during intralymphatic delivery. J Immunother. 32: 66-78. [PubMedID: 19307995] A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/NegativeWiesner, M. et al. (2008). Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 3(1): e1464. [PubMedID: 18213373] A*02:01/ELAGIGILTV (MelanA / MART-1)A*02:01/CLGGLLTMV (EBV LMP-2)Wilkinson, R. et al. (2006). Numerical and functional assessment of blood dendritic cells in prostate cancer patients. The Prostate 66: 180-192. [PubMedID: 16173035] A*02:01/GILGFVFTL (Influenza A MP)A*02:01/VISNDVCAQV (PSA-1)Wolfl, M. et al. (2007). Activation-induced expression of CD137 permits detection, isolation and expansion of the full repertoire of CD8+ T-cells responding to antigen without requiring knowledge of epitope-specificities. Blood 110: 201-210. [PubMedID: 17371945] A*02:01/ELAGIGILTV (MelanA / MART-1)B*07:02/TPRVTGGGAM (HCMV pp65)A*02:01/KLVALGINAV (HCV NS1)Yagi, H. et al. (2006). Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer. Res. 66: 10136-10144. [PubMedID:17047078] A*02:01/EYLQLVFGI (MAGE-2)A*02:01/IMPKAGLLI (MAGE-3)Yan, M. et al. (2008). Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy. Cancer Res. 68: 8058-8065 [PubMedID: 18829564] A*02:01/TLPGYPPHV (PAX5)Yang, S. et al. (2008). Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells. Cancer Immunol. Immunother. 58: 503-513. [PubMedID: 18690438] A*02:01/YLSGANLNL (CEA)AdenovirusFinn, JD. et al. (2010). Proteasome inhibitors decrease AAV2 capsid-derived peptide epitope presentation on MHC class I following transduction. Molecular Therapy. 18: 135-142 [PubMedID:19904235] B*07:02/VPQYGYLTL (AAV-2)Fujita, Y. et al. (2008) Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 31: 665-674. [PubMedID: 18600178] B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)A*02:01/NLVPMVATV (CMV pp65)A*02:01/FLYALALL (EBV LMP-2)A*02:01/CLGGLLTMV (EBV LMP-2)Kaka, AS. et al. (2008). Using dendritic cell maturation and IL-12 producing capacity as markers of function: A cautionary tale. J Immunother. 31: 359-369. [PubMedID: 18391760] A*01:01/TLDGQNLLY (Adenovirus 5 Hexon)A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)Karlsson, H. et al. (2007) Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus and Epstein-Barr virus. J. Immunother. 30: 544-556. [PubMedID: 17589295] A*02:01NLVPMVATV (HCMV pp65)B*07:02/RPHERNGFTVL (HCMV pp65)B*07:02/TPRVTGGGAM (HCMV pp65)A*02:01/CLGGLLTMV (EBV LMP-2)A*02:01/GLCTLVAML (EBV BMLF-1)B*07:02/RPPIFIRRL (EBV EBNA-3A)B*08:01/RAKFKQLL (EBV BZLF-1)A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)A*01:01/TLDGQNLLY (Adenovirus 5 Hexon)B*07:02/KPYSGTAYNAL (Adenovirus Hexon)Leen, AM. et al. (2008). Identification of Hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 82: 546-554. [PubMedID: 17942545] A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)A*01:01/TLDGQNLLY (Adenovirus 5 Hexon)B*07:02/KPYSGTAYNAL (Adenovirus Hexon)B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)Micklethwaite, KP. et al. (2008). Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 112: 3974-3981 [PubMedID: 18768783] A*01:01/TDLGQNLLY (Adenovirus 5 Hexon)Mingozzi, F. et al. (2007). CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13: 419-422. [[PubMedID: 17369837] B*07:02/VQPYGYLTL (AAV-2)Pien, GC. et al. (2009). Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.Journal Clin. Invest. doi:10.1172/JCI36891. [PubMedID: 19436115] A*01:01/SADNNNSEY (AAV-2)B*07:02/VQPYGYLTL (AAV-2)B*07:02/IPQYGYLTL (AAV-8)B*07:02/IPRRIRQGL (HIV-1 env)B*07:02/RPPIFIRRL (EBV EBNA-3A)Cytomegalovirus (CMV)Böhm, V. et al. (2008). Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy. Med. Microbiol. Immunol. 197:135-144. [PubMedID:18340461] H-2Ld/YPHFMPTNL (MCMV)Bollard, C.M. et al. (2007).Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 110: 2838-45. [PubMedID: 17609424] A*02:01/CLGGLLTMV (EBV LMP-2)A*02:01/NLVPMVATV (HCMV pp65)Brennan, R.M. et al. (2007).Predictable ab T cell receptor selection towards an HLA-B*35:01-restricted human cytomegalovirus epitope. J. Virol. 81: 7269-7273. [[PubMedID: 17459926] B*35:01/IPSINVHHY(HCMV pp65)Cantisan, S. et al. (2009). Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation. Clin. Vaccine Immunol. 16: 1429-1438 [PubMedID: 19656991] A*02:01/NLVPMVATV (CMV pp65)Christmas, SE. et al. (2009). Cytomegalovirus-specific CD8+ T ells do not develop in all renal transplant patients at risk of virus infection. Transpl. Immunol. 22: 99-104 [PubMedID: 19635559] A*02:01/NLVPMVATV (CMV pp65)Crough, T. et al. (2007). Symptomatic and asymptomatic viral recrudescence in solid organ transplant recipients and its relationship with antigen-specific CD8+ T-cell response. J. Virol. 81: 11538-42. [PubMedID: 17686874] A*02:01/NLVPMVATV (CMV pp65)A*01:01/VTEMDTLLY (CMV pp50)B*07:02/TPRVTGGGAM (CMV pp65)Czesnikiewicz-Guzik, M. et al. (2008) T cell subset-specific susceptibility to aging.Clin Immunol. 127: 107-118 [[PubMedID: 18222733] A*02:01/NLVPMVATV (CMV pp65)Dander, E. et al. (2008). Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library. Exp. Hematol. 36: 473-485. [PubMedID: 18261836] A*02:01/NLVPMVATV (CMV pp65)B*07:02/TPRVTGGGAM (CMV pp65)B*07:02/RPHERNGFTVL (CMV pp65)A*01:01/YSEHPTFTSQY (CMV pp65)B*35:01/IPSINVHHY (CMV pp65)Davies, JK. et al. (2008). Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of two phase I studies. Blood. 112: 2232-2241 [PubMedID: 18617635] A*02:01/NLVPMVATV (CMV pp65)Davies, JK et al (2008). Induction of alloanergy in human donor T cells without loss of pathogen or tumour immunity. Transplantation. 86: 854-864 [PubMedID: 18813111] A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/NLVPMVATV (CMV pp65)Fujita, Y. et al. (2008) Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 31: 665-674. [PubMedID: 18600178] B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)A*02:01/NLVPMVATV (CMV pp65)A*02:01/FLYALALL (EBV LMP-2)A*02:01/CLGGLLTMV (EBV LMP-2)Gerdemann, U. et al. (2009). Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Molecular Therapy. 17: 1616-1625. [PubMedID: 19584818] A*02:01/NLVPMVATV (CMV pp65)B*07:02/TPRVTGGGAM (CMV pp65)Griffioen, M. et al (2008). Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica. 93: 1535-1543 [PubMedID: 18768532] Hayashi, D. et al. (2008). Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-1-associated myelopathy. J Neuroimmunol. 200: 115-124 [PubMedID: 18639344] A*02:01/LLFGYPVYV (HTLV Tax)A*02:01/CLGGLLTMV (CMV LMP2)A*02:01/NLVPMVATV (CMV pp65)A*02:01/SLYNTVATL (HIV gag17)Horlock, C. et al. (2009). ELISPOT and functional T cell analyses using HLA mono-specific target cells. J Immunol. Methods 350: 150-160. [PubMedID: 19729014] Karlsson, H. et al. (2007) Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus and Epstein-Barr virus. J. Immunother. 30: 544-556. [PubMedID: 17589295] A*02:0/NLVPMVATV (HCMV pp65)B*07:02/RPHERNGFTVL (HCMV pp65)B*07:02/TPRVTGGGAM (HCMV pp65)A*02:01/CLGGLLTMV (EBV LMP-2)A*02:01/GLCTLVAML (EBV BMLF-1)B*07:02/RPPIFIRRL (EBV EBNA-3A)B*08:01/RAKFKQLL (EBV BZLF-1)A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)A*01:01/TLDGQNLLY (Adnovirus 5 Hexon)B*07:02/KPYSGTAYNAL (Adenovirus Hexon)Karlsson, H. et al. (2008). Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T cell responses. Blood 112: 532-541 [PubMedID: 18445691] A*02:0/NLVPMVATV (HCMV pp65)B*07:02/RPHERNGFTVL (HCMV pp65)B*07:02/TPRVTGGGAM (HCMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)B*07:02/RPPIFIRRL (EBV EBNA-3A)B*08:01/RAKFKQLL (EBV BZLF-1)Leen, A.M. et al. (2006). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12: 1160-1166. [PubMedID: 16998485] A*02:01NLVPMVATV (HCMV pp65)A*24:01/VYALPLKML (HCMV pp65)A*24:01/QYDPVAALF (HCMV pp65)B*07:02/RPHERNGFTVL (HCMV pp65)B*07:02/TPRVTGGGAM (HCMV pp65)Li Pira, G. et al. (2008) Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems. Potential applications for adoptive cellular immunoreconstitution. J Immunother. 31: 762-770. [PubMedID: 18779743] A*02:01/NLVPMVATV (CMV pp65)Li Pira, G. et al. (2008). Evaluation of antigen specific T-cell responses with a miniaturized and automated method. Clin. Vaccine Immunol. 15: 1811-1818 [PubMedID: 18945878] A*02:01/NLVPMVATV (CMV pp65)Li Pira, G. et al. (2006). A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes. Transfusion 46: 2053-62. [PubMedID: 17176316] A*02:01/NLVPMVATC (CMV pp65)A*02:01/SLYNTVATL (HIV gag p17)Martin-Donnaire, T. et al. (2009). Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor. Bone Marrow Transplantation. 44: 213-225 [PubMedID: 19252533] A*02:01/NLVPMVATV (CMV pp65)A*01:01/YSEHPTFTSQY (CMV pp65)A*24:02/QYDPVAALF (CMV pp65)A*24:02/VYALPLKML (CMV pp65)B*35:01/IPSINVHHY (CMV pp65)Mustjoki, S. et al. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23: 1398-1405 [PubMedID: 19295545] Paine, A. et al. (2007). Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. Transfusion 47: 2143-52. ]PubMedID: 17958544] A*02:01/NLVPMVATV (CMV pp65)A*02:01/VLHDDLLEA (HA-1) - Negative controlPerseghin, P. et al. (2008). Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device. Transfusion. 48: 1644-1649. [PubMedID: 18513258] A*02:01/NLVPMVATV (CMV pp65)Pita-Lopez, ML. et al. (2009). Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors. Immunity & Ageing. 6: 11 [PubMedID:19715573] A*02:01/NLVPMVATV (CMV pp65)Reker Hadrup, S. et al. (2006). Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J. Immunol. 176: 2645-2653.[PubMedID: 16456027] A*02:01NLVPMVATV (HCMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/ILKEPVHGV (HIV-1 pol)Rosenthal, R. et al. (2009). Differential responsiveness to IL-2, IL-7 and Il-15 common receptor g chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother. 32: 252-261. [PubMedID: 19242375] A*02:01/NLVPMVATV (CMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/SLSAYIIRV (Vaccinia Virus H3L)A*02:01/KVDDTFYYV (Vaccinia Virus C7L)Schub, A et al. (2009). CMV-specific TCR transgenic T cells for immunotherapy. J Immunol: 183: 6819-6830 [PubMedID: 19864595] A*01:01/YSEHPTFTSQY (CMV pp65)A*02:01/NLVPMVATV (CMV pp65)B*35:01/IPSINVHHY (CMV pp65)Schultz-Thater, E. et al. (2008). Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool. Journal of Translational Medicine. 6: 58 [PubMedID: 18925935] A*02:01/NLVPMVATV (CMV pp65)A*02:01/GLCTLVAML (EBV BMLF1)A*02:01/CLGGLLTMV (EBV LMP2)A*02:01/GILGFVFTL (Influenza MP)Schwanninger, A. et al. (2008). Age-related appearance of a CMV-specific high-avidity CD8+ T cells clonotype which does not occur in young adults. Immunity & Ageing. 5:14 [PubMedID: 19014475] A*02:01/NLVPMVATV (CMV pp65)Sester, U. et al. (2008). PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant. 8: 1486-1497 [PubMedID: 18510628] A*01:01/YSEHPTFTSQY (CMV pp65)Suneetha, PV. et al. (2009). Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. J Immunol. Methods 342: 33-48. [PubMedID: 19135447] A*02:01/GILGFVFTL (Influenza MP)A*02:01/NLVPMVATV (CMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/CINGVCWTV (HCV NS3)Tanaka, K. et al. (2007). Role of the indigenous microbiota in maintaining the virus-specific CD8 memory T cells in the lung of mice infected with murine cytomegalovirus. J. Immunol. 178: 5209-5216. [PubMedID: 17404304] H-2Ld/YPHFMPTNL (MCMV)Tey, S-K. et al. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13: 913-24. [PubMedID: 17640595] B*08:01/RAKFKQLL (EBV BZLF-1)A*02:01/NLVPMVATV (CMV pp65)Waller, E. et al. (2007). Differential co-stimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28-CD45RA hi) CD8+ T cells. Blood. 110: 4360-6. [PubMedID: 17878400] A*02:01/NLVPMVATV (CMV pp65)B*07:02/TPRVTGGGAM (CMV pp65)Weinberger, B et al. (2009). CD28-CD8+ T cells do not contain unique clonotypes and are therefore dispensable. Immunol Lett. 127: 37-32 [PubMedID: 19715728] A*02:01/NLVPMVATV (CMV pp65)Widmann, T. et al. (2008) Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE. 3: e3634 [PubMedID: 18982061] A*01:01/YSEHPTFTSQY (CMV pp65)A*02:01/NLVPMVATV (CMV pp65)A*02:01/VLEETSVML (CMV 1E1)B*07:02/TPRVTGGGAM (CMV pp65)B*07:02/RPHERNGTVL (CMV pp65)Wilson, J. et al. (2009). Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J. Exp. Med. 206: 387-398 [PubMedID: 19171763] A*02:01/NLVPMVATV (CMV pp65)Wynn, KK. et al. (2008). Impact of lonal competition for peptide-MHC complexes on CD8+ T cell repertoire selection in a persistent viral infection. Blood. 111: 4283-4292. [PubMedID: 18270323] B*35:08/CPSQEPMSIYVY (CMV pp65)B*35:08/FPTKDVAL (CMV pp65)Yang, R. et al. (2008) Human Cytomegalovirus specific CD8+ T lymphocytes display interferon-g secretion impairment in kidney transplant recipients with pp65 antigenemia. Transplantation Proc. 40: 3500-3504 [PubMedID: 19100424] A*02:01/NLVPMVATV (CMV pp65)Yao, J. et al. (2008). Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis. 46:e96-105. [PubMedID: 18419478] A*02:01NLVPMVATV (HCMV pp65)B*07:02/TPRVTGGGAM (CMV pp65)Zhang, J-Y. et al. (2008) Cutting Edge: Programmed Death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limiting hepatitis B virus infection. J. Immunol. 181: 3741-3744 [PubMedID: 18768824] A*02:01/NLVPMVATV (CMV pp65)Zhang, X. et al. (2006). Human bone marrow: A reservoir for 'enhanced effector memory' CD8+ T cells with potent recall function. J. Immunol. 177: 6730-6737. [[PubMedID: 17082586] A*02:01/NLVPMVATV (CMV pp65)Zhong, J. et al. (2008). Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS one. 3:e3256 [PubMedID: 18806877] A*02:01/NLVPMVATV (CMV pp65)A*01:01/VTEHDTLLY (CMV pp50)Wang, X. et al. (2007). Induction of potent CD8+ T cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type I gp120. J. Virol. 81: 10009-16. [PubMedID: 17609261] A*02:01/NLVPMVATV (CMV pp65)B*07:02/TPRVTGGGAM (CMV pp65)Epstein-Barr Virus (EBV)Archbold, J.K. et al. (2006).Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is resultant of highly focused, peptide-dependent structural mimicry. J.Biol. Chem. 281: 34324-34332. [PubMedID: 16963442] B*08:01/FLRGRAYGL (EBV EBNA-3A)Bell, MJ. et al. (2008) Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. J. Infect. Dis. 197: 1594-1597 [PubMedID: 18419576] B*08:01/YNLRRGIAL (EBV EBNA1)B*08:01/YNLRRGTAL (EBV EBNA1)Bell, MJ. et al. (2009) An HLA-A2-restricted T cell epitope mapped to the BNLF2a immune evasion protein of EBV that inhibits TAP. J Virol.83: 2783-2788 [PubMedID: 19129449] A*02:01/VLFGLLCLL (EBV BNLF2a)Bollard, C.M. et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 110: 2838-45. [PubMedID: 17609424] A*02:01/CLGGLLTMV (EBV LMP-2)A*02:01NLVPMVATV (HCMV pp65)Borg, N.et al. (2005). The CDR3 regions of an immunodominant T cell receptor dictate the ‘energetic landscape’ of peptide-MHC recognition. Nat. Immunol. 6: 171-180. [PubMedID:15640805] B*08:01/FLRGRAYGL (EBV EBNA-3A)Burrows, JM. et al. (2008) Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. Mol. Immunol. 45: 1818-1824. [PubMedID: 17981331] B*35:01/QPAPENAYQAY (EBV BZLF)Davies, JK et al (2008). Induction of alloanergy in human donor T cells without loss of pathogen or tumour immunity. Transplantation. 86: 854-864 [PubMedID: 18813111] A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/NLVPMVATV (CMV pp65)de Angelis, B. et al. (2009) Generation of Epstein-Barr virus specific cytotoxic T lymphocytes resistant to the immunosuppresive drug tacrolimus (FK506). Blood. 114: 4784-4791 [PubMedID:19759356] A*11:01/IVTFDSVIK (EBV EBNA3B)A*11:01/AVFDRKSDAK (EBV EBNA3B)B*08:01/QAKWRLQTL (EBV EBNA3A)B*08:01/RAKFKQLL (EBV BZLF1)Elliott, S. et al. (2007). A phase I trial of a CD8+ T cell peptide epitope-based vaccine for infectious mononucleosis. J. Virol. 82: 1448-57. [PubMedID: 18032491] B*08:01/FLRGRAYGL (EBV EBNA-3A)B*08:01/RAKFKQLL (EBV BZLF-1)Fujita, Y. et al. (2008) Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 31: 665-674. [PubMedID: 18600178] B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)A*02:01/NLVPMVATV (CMV pp65)A*02:01/FLYALALL (EBV LMP-2)A*02:01/CLGGLLTMV (EBV LMP-2)Gandhi, M.K. et al. (2007). Galectin-1 mediated suppression of EBV-specific T-cell immunity in classical Hodgkin-s lymphoma. Blood 110: 1326-9. [[PubMedID: 17438085] A*02:01/CLGGLLTMV (EBV LMP-2)Gandhi, M.K. et al. (2007). Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am. J. Transplant. 7: 1293-1299. [PubMedID: 17425621] B*08:01/FLRGRAYGL (EBV EBNA-3A)Gandhi, M.K. et al. (2006). Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T cell function in Hodgkin lymphoma patients. Blood 108: 2280-2289. [PubMedID: 16757686] A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/CLGGLLTMV (EBV LMP-2)B*07:02/RPPIFIRRL (EBV EBNA-3A)B*08:01/FLRGRAYGL (EBV EBNA-3A)B*08:01/RAKFKQLL (EBV BZLF-1)Griffioen, M. et al (2008). Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica. 93: 1535-1543 [PubMedID: 18768532] Han, S. et al. (2009). Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. J. Hematol & Oncol. 2: 34. [PubMedID:19660111] A*24:02/TYGPVFMCL (EBV LMP2)Hart, D P. et al (2008). Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. [PubMedID: 18305579] A*02:01/CLGGLLTMV (EBV LMP-2)Hofer, S. et al. (2005). Dendritic cells regulate T-cell de-attachment through the integrin-interacting protein CYTIP. Blood 107: 1003-1009. [PubMedID: 16204317] A*02:01/GLCTLVAML (EBV BMLF-1)Jarvis, LB. et al. (2008) Human leukocyte antigen class I-restricted immunosuppression by human CD8+ regulatory T cells requires CTLA-4-mediated interaction with dendritic cells. Human Immunology. 69:687-695 [PubMedID: 18817831] Karlsson, H. et al. (2007) Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus and Epstein-Barr virus. J. Immunother. 30: 544-556. [PubMedID: 17589295] A*02:01NLVPMVATV (HCMV pp65)B*07:02/RPHERNGFTVL (HCMV pp65)B*07:02/TPRVTGGGAM (HCMV pp65)A*02:01/CLGGLLTMV (EBV LMP-2)A*02:01/GLCTLVAML (EBV BMLF-1)B*07:02/RPPIFIRRL (EBV EBNA-3A)B*08:01/RAKFKQLL (EBV BZLF-1)A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)A*01:01/TLDGQNLLY (Adnovirus 5 Hexon)B*07:02/KPYSGTAYNAL (Adenovirus Hexon)Karlsson, H. et al. (2008). Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T cell responses. Blood 112: 532-541 [PubMedID: 18445691] A*02:01NLVPMVATV (HCMV pp65)B*07:02/RPHERNGFTVL (HCMV pp65)B*07:02/TPRVTGGGAM (HCMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)B*07:02/RPPIFIRRL (EBV EBNA-3A)B*08:01/RAKFKQLL (EBV BZLF-1)Landmeier, S. et al. (2009). Activated humangd T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes. J. Immunother. 32: 310-321. [PubMedID: 19242369] A*02:01/FLYALALLL (EBV LMP-2)B*08:01/RAKFKQLL (EBV BZLF-1)Lehner, M. et al. (2007). Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. J Immunother. 30: 312-322. [PubMedID: 17414322] A*02:01/GLCTLVAML (EBV BMLF-1)Louis, CU. et al. (2008). Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 113: 2442-2450. [PubMedID: 18971421] A*11:01/AVFDRKSDAK (EBV EBNA3B)Lutzky, VP. et al. (2009). Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients. Immunol & Cell Biol. 87: 481-488.[PubMedID: 19468283] A*11:01/SSCSSCPLSK (EBV LMP-2)Miles, J.J. et al. (2006). TCRa genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope. J. Immunol. 177: 6804-6814. [PubMedID: 17082594] B*35:01/HPVGEADYFEY (EBV EBNA-1)Mustjoki, S. et al. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. epub ahead of print. [PubMedID: 19295545] Nehring, A.K. et al. (2007). Epstein-Barr virus T-cell immunity despite rituximab. Br. J. Haematol. 136: 628-632. [PubMedID: 17223914] B*08:01/FLRGRAYGL (EBV EBNA-3A)Reker Hadrup, S. et al. (2006). Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J. Immunol. 176: 2645-2653. [PubMedID: 16456027] A*02:01NLVPMVATV (HCMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/ILKEPVHGV (HIV-1 pol 476-484)Schultz-Thater, E. et al. (2008). Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool. Journal of Translational Medicine. 6: 58 [PubMedID: 18925935] A*02:01/NLVPMVATV (CMV (pp65)A*02:01/GLCTLVAML (EBV BMLF1)A*02:01/CLGGLLTMV (EBV LMP2)A*02:01/GILGFVFTL (Influenza MP)Smith, C. et al. (2009) Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self aggregation. Blood. 113: 6148-6152. [PubMedID: 19372256] B*35:01/YPLHEQHGM (EBV EBNA-3A)B*35:01/IPSINVHHY (CMV pp65)A*02:01/NLVPMVATV (CMV pp65)A*02:01 YLQQNWWTL (EBV LMP-1)A*02:01/CLGGLLTMV (EBV LMP-2)Smith, C. et al. (2009). Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1 mediated suppression. J Virol. 83: 6192-6198. [PubMedID: 19357166] A*02:01/CLGGLLTMV (EBV LMP-2)B*08:01/FLRGRAYGL (EBV EBNA-3A)Smith, C. et al.(2006).; Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J. Immunol. 177: 4897-4906. [PubMedID: 16982932] A*02:01/CLGGLLTMV (EBV LMP-2)B*35:01/HPVGEADYFEY (EBV EBNA-1)Suneetha, PV. et al. (2009). Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. J Immunol. Methods 342: 33-48. [PubMedID: 19135447] A*02:01/GILGFVFTL (Influenza MP)A*02:01/NLVPMVATV (CMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/CINGVCWTV (HCV NS3)Tellam, J. et al. (2007). Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J. Exp. Med. 204: 525-532. [PubMedID: 17312009] B*08:01/FLRGRAYGL (EBV EBNA-3A)Tellam, J. et al. (2007). Translation efficiency of EBNA1 encoded by lymphocryptoviruses influences endogenous presentation of CD8+ T cell epitopes. Eur. J. Immunol. 37: 328-337. [PubMedID: 17236233] B*08:01/FLRGRAYGL (EBV EBNA-3A)Tellam, J. et al. (2008). Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. PNAS. 105: 9319-9324 [PubMedID: 18591662] B*35:08/HPVGEADYFEY (EBV EBNA1)Tey, S-K. et al. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13: 913-24. [PubMedID: 17640595] B*08:01/RAKFKQLL (EBV BZLF-1)A*02:01/NLVPMVATV (CMV pp65)Tuuminen, T. et al. (2007). Human CD8 T cell memory generation in Puumala Hantavirus infection occurs after the acute phase and is associated with boosting of EBV-specific CD8 memory T cells. J.Immunol. 179: 1988-1995. A*02:01/GLCTLVAML (EBV BMLF-1)Tynan, F.E. et al. (2007). A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatability complex class I molecule. Nat. Immunol 8: 268-276. [PubMedID: 17259989] Tynan, F.E. et al. (2005). T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat. Immunol. 6: 1114-1122. [PubMedID: 16186824] Vera, JF. et al. (2009). Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Molecular Therapy.17: 880-888.[PubMedID: 19259067] B*08:01/RAKFKQLL (EBV BZLF-1)B*08:01/QAKWRLQTL (EBV EBNA-3A)A*02:01/GLCTLVAML (EBV BMLF-1)Hepatitis B Virus (HBV)Boettler, T. et al. (2006). Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionality and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virology. 80: 3532-3540. [PubMedID:16537621 A*02:01/FLPSDFFPSV (HBV core)A*02:01/FLLTRILTI (HBV envelope)A*02:01/WLSLLVPFV (HBV surface antigen)A*02:01/GLSRYVARL (HBV polymerase)Chen, W. et al. (2008). HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatology Research. epub ahead of print A*02:01/FLPSDFFPSV (HBV core)Chen, W. et al. (2008) Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response. Clinical Immunol. 129-295-303 [PubMedID: 18774748] A*02:01/FLPSDFFPSV (HBV core)Evans, A. et al. (2008). Programmed death 1 (PD-1) expression during antiviral treatment of chronic hepatitis B: Impact of HBeAg Seroconversion. Hepatology. 48: 759-769 [PubMedID: 18697210] A*02:01/FLPSDFFPSV (HBV core)A*02:01/FLLTRILTI (HBV sAg)A*02:01/NLVPMVATV (CMV pp65)Gehring, A.J. et al. (2007). The level of viral antigen presented by hepatocytes influences CD8 T cell function. J. Virol. 81: 2940-2949. [PubMedID: 17202217] Nystrom, J. et al. (2010) Improving on the Ability of Endogenous Hepatitis B Core Antigen to Prime Cytotoxic T Lymphocytes. Journal of Infectious Diseases 201: 1867-1879 [PubMedID:20446851] H-2Kb/MGLKFRQL (HBcAg 93-100Komatsu, H. et al .(2010). Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus. BMC Infectious Diseases 10: 103-113 [PubMedID:20423521] A*24:02/EYLVSFGVW (HBV pol 756-764)A*24:02/KYTSFPWLL (HBV core 117-125)Liu, H-G. et al. (2007). The high prevalence of the I27 mutant HBcAg18-27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope. Clin. Immunol. 125: 337-45. [PubMedID:17900990] A*02:01/FLPSDFFPSV (HBV core)A*02:01/FLPSDFFPSI (HBV core)Lopes, AR. et al. (2008). Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection. J. Clin. Invest. 118: 1835-1845 [PubMedID: 18398508] A*02:01/FLPSDFFPSV (HBV core)A*02:01/FLLTRILTI HBV env)A*02:01/GLSRYVARL (HBV pol)A*02:01/GILGFVFTL (Influenza MP)Peng, G. et al. (2007). PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol. Immunol. 45: 963-70. [PubMedID:17868872] A*02:01/FLPSDFFPSV (HBV core)A*11:01/YVNVNMGLK (HBV core)Phillips, S. et al. (2010). CD8+ T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J. Immunol. 184: 287-295 [PubMedID:19949099] A*02:01/FLPSDFFPSV (HBV core)Schirmbeck, R. et al. (2008). The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Molecular Therapy. 16: 1609-1616 [PubMedID: 18612271] H-2Ld/IPQSLDWWTSL (HBV SAg)Wieland, A. et al. (2009). Silencing an immunodominant epitope of hepatitis B surface antigen reveals and alternative repertoire of CD8 T cell epitopes of this viral antigen. Vaccine. 23: 114-119 [PubMedID: 19818719] H-2Ld/IPQSLDWWTSL (HBV SAg)Wortmann, A. et al. (2007). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16: 154-62. [PubMedID: 17848961 H-2Ld/IPQSLDSWWTSL (HBV surface antigen )Zhang, Z. et al. (2009) Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell developmet in acute self-limited hepatitis B patients. J. Hepatol. 50: 1163-1173 [PubMedID: 19395117] A*02:01/FLLTRILTI (HBV env)A*02:01/WLSLLVPFV (HBV SAg)A*02:01/FLLSLGIHL (HBV pol)A*02:01NLVPMVATV (CMV pp65)A*02:01/GILGFVFTL (Influenza MP)Hepatitis C Virus (HCV)Caetano, J. et al. (2008). Differences in Hepatitis C Virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV . J.Virol. 82: 7567-7577. [PubMedID:18480446] A*02:01/CINGVCWTV (HCV N53)A*02:01/DLMGYIPAV (HCV core)Fytili, P. et al. (2008) Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine. 26: 3818-3826 [PubMedID: 18582999] A*02:01/CINGVCWTV (HCV NS3)Golden-Mason, L. et al.(2008). Cutting Edge: Programmed Death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: Race-dependent differences. J. Immunol. 180: 3637-3641. [PubmedID: 18322167] B*35:01/HPNIEEVAL (HCV NS3)Golden-Mason, L. et al. (2007). Upregulation of PD-1 expression on circulating and intrahepatic HCV-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81: 9249-58. [PubMedID:17567698] Jeong, H-Y. et al. (2007). Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J. Leukoc. Biol. 83: 755-64. [PubMedID:18086898] A*02:01/CINGVCWTV (HCV N53)Golden-Mason, L. et al. (2009) Negative immune regulatory Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 83: 9122-9130 [PubMedID:19587053] A*02:01/KLVALGINAV (HCV NS3)A*02:01/CINGVCWTV (HCV NS3)Kasprowicz, V. et al. (2007). High PD-1 expression on HCV-specific CD8+ and CD4+ T cells during acute Hepatitis C irrespective of clinical outcome. J. Virol. 82: 3154-60. [PubMedID:18160439] A*02:01/CINGVCWTV(HCV N53)A*02:01/KLVALGINAVKasprowicz, V. et al 2008). Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J. Clin.Invest. 118: 1143-1153 [PubMedID:18246203] A*02:01/GILGFVFTL (Influenza MP)A*02:01/CVNGSCFTV (Influenza NA)Kasprowicz, V. et al (2010). HCV sequence variation induces an HCV-specific T cell phenotype analogous to spontaneous resolution. J. Virol. 84: 1656-1663 [PubMedID: 19906915] A*01:01/ATDALMGTY (HCV NS3)A*02:01/CINGVCWTV (HCV NS3)A*02:01/GLQDCTMLV (HCV NS5B)B*07:02/GPRLGVRAT (HCV core)Langhans, B. et al. (2006). Presentation of the HCV-derived lipopeptide LP20-44 by dendritic cells enhances function of in vitro-generated CD4+ T cells via up-regulation of TLR2.Vaccine 24: 3066-3075. [PubMedID: 16504351] A*02:01/YLLPRRGPRL (HCV core)Rutebemberwa, A. et al. (2008). High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J. Immunol. 181: 8215-8225 [PubMedID: 19050238] A*01:01/ATDALMTGY (HCV NS3)A*02:01/RLWHYPCTV (HCV E23)Smyk-Pearson, S. et al. (2008). Spontaneous recovery in acute human HCV infection: functional T cell thresholds and relative importance of CD4 help. J. Virol. 82: 1827-37. [PubMedID:18045940 A*02:01/CINGVCWTVHuman Immunodeficiency Virus (HIV)Almeida, J. et al. (2007). Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-85. [PubMedID:17893201] B*2705/KRWIILGLNK (HIV-1 gag p24)A*03:01/QVPLRPMTYK (HIV-1 nef)A*03:01/RLRPGGKKK (HIV-1 gag p17)B*07:02/GPGMKARVL (HIV-1 gag)Andersen, MH. et al. (2005). Spontaneous immunity against Bcl-XL in cancer patients.J. Immunol. 175: 2709-2714. [PubMedID:16081848 A*02:01/ILKEPVHGV (HIV-1 pol)Bailey, JR. et al. (2008). Transmission of human immunodeficiency virus type I from a patient who developed AIDS to an elite suppressor. J Virol. 82: 7395-7410 [PubMedID: 18495769] B*27:05/KRWIILGLNK (HIV-1 gag p24)Bridgeman, A. et al. (2009). Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine. 28: 474-483 [PubMedID:19853074] H-2Kd/AMQMLKETI (HIV-1)Brockman, MA. et al. (2009). IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood. 114: 346-356. [PubMedID:19365081] A*02:01/SLYNTVATL (HIV-1 gag)B*27:05/KRWIILGLNK (HIV-1 gag)Cooper, D. et al. (2008). Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice. J. Virol. 82: 207-19. [PubMedID:17942549] H-2Kd/AMQMLKETI (HIV gag)Cottingham, M.G. et al. (2006). Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Clin. Vaccine Immunol. 13: 747-757. [PubMedID: 16829611] H-2Dd/RGPGRAFVTI (HIV-1 gp120Decrion, A.Z. et al. (2007). A subset of functional effector-memory CD8+ T lymphocytes in human immunodeficiency virus-infected patients. Immunology 121: 405-15. [PubMedID:17376193] A*02:01/ILKEPVHCV (HIV Pol)A*02:01/SLYNTVATL (HIV gag)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/NLVPMVATV (CMV pp65)Earl, PL. et al. (2009). Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. 27: 5885-5895. [PubMedID: 19654066] H-2Kd/AMQMLKETI (HIV-1)Harari, A. et al. (2008). An HIV-1 clade C DNA prime, NYVAC boost regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 205: 63-77 [PubMedID: 18195071] A*01:01/YSENSSEYY (HIV-1 env)Jones, RB. et al. (2008). Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frqeuencies in progressive HIV-1 infection. J. Exp. Med. 205: 2763-2779 [PubMedID: 19001139] A*02:01/NLVPMVATV (CMVpp65)A*02:01/GLCTLVAML (EBV BMLF1)A*02:01ILKEPVHGV (HIV-1 Pol)A*02:01/SLYNTVATL (HIV-1 gag17)B*07:02/TPRVTGGGAM (CMV pp65)Lecuroux, C. et al. (2009). Identification of a particular HIV-specific CD8+ T cells subset with a CD27+ CD45RO-/RA+ phenotype and memory characterisation after initiation of HAART during acute primary HIV infection. 113: 3209-3217 [PubMedID: 19098272] A*02:01/SLYNTVATL (HIV-1 gag)A*02:01/ILKEPVHGV (HIV-1 pol)A*03:01/RLRPGGKKK (HIV-1 gag)A*03:01/QVPLRPMTYK (HIV-1 nef)A*24:02/RYPLTFGWCY (HIV-1 nef)B*07:02/IPRRIRQGL (HIV-1 env)B*08:01/GEIYKRWII (HIV-1 gag)B*08:01/FLKEKGGL (HIV-1 nef)B*27:05KRWIILGLNK (HIV-1 gag)A*02:01/GLCTLVAML (EBV BMLF-1)B*08:01/RAKFKQLL (EBV BZLF-1)Lichterfeld, M. et al. (2008). Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1in progressors. Blood. 112: 3679-3687 [PubMedID: 18728248] Lichterfield, M. et al. (2007). A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J. Exp. Med. 204: 2813-24. [PubMedID:18025130] B*27:05/KRWIILGLNK (HIV-1 gag)B*27:05/KRWIIMGLNK HIV-1 gag)Rawson, P.M. et al. (2007). Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat. Med. 13: 1431-1439. [PubMedID:18026114 A*02:01/LLQDSVDFSL (Vimentin)A*02:01/QLFNHTMFI (Non-muscle myosin)A*02:01/VLMIKALEL (Non-muscle myosin)A*02:01/FLGMESCGI (Actin)Saez-Cirion, A. et al. (2009). Heterogeneity in HIV Suppression by CD8 T cells from HIV controllers: Association with gag-specific CD8 T cell responses. J. Immunol. 182: 7828-7837. [PubMedID: 19494307] A*02:01/SLYNTVATL (HIV-1 gag)A*02:01/ILKEPVHGV (HIV-1 pol)A*03:01/RLRPGGKKK (HIV-1 gag)A*03:01/QVPLRPMTYK (HIV-1 nef)B*27:05/KRWIILGLNK (HIV-1 gag)Salisch, NC. et al. (2010). Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol. 184: 476-487. [PubMedID: 19949078] A*02:01/SLYNTVATL (HIV-1 gag)A*03:01/RLRPGGKKK (HIV-1 gag)A*03:01/QVPLRPMTYK (HIV-1 nef)B*07:02/IPRRIRQGL (HIV-1 env)B*08:01/EIYKRWII (HIV-1 gag)B*08:01/FLKEKGGL (HIV-1 nef)B*27:05/KRWIILGLNK (HIV-1 gag)Shephard, E. et al. (2008). A multigene HIV type 1 subtype C modified vaccinia ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res. Hum. Retroviruses. 24: 207-217. [PubMedID:18240963] H-2Dk/VYYDPSKDLIA (HIV-RT)H-2Dd/RGPGRAFVTI (HIV-env)Streeck, H. et al. (2008). Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Medicine. 5: e100 [PubMedID: 18462013] Streeck, H. et al. (2008). Immune-driven recombination and loss of control after HIV superinfection. J Exp. Med. 205: 1789-1796 [PubMedID: 18625749] B*27:05/KRWIIMGLNK (HIV-1 gag p24)Vali, B. et al. (2008). HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS one. 3: e3454. [PubMedID: 18941622] Yu, X. et al. (2007). Random T-cell receptor recruitment in human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells from genetically identical twins infected with the same HIV-1 strain. J. Virol. 81: 12666-9. [PubMedID: 17804503] B*40:01/IEELRQHLL (HIV-1 pol)B*40:01/IETVPVKL (HIV-1 pol)B*40:01/KEKGGLEGL (HIV-1 nef)A*02:01/YTAFTIPSV (HIV-1 pol)A*02:01/SLYNTVATL (HIV-1 gag)Zhang, J-Y. et al. (2007). PD-1 upregulation is correlated with HIV-specific memory CD8+ T cell exhaustion in typical progressors, but not in long-term non-progressors. Blood 109:4671-4678. [PubMedID:17272504] A*02:01/SLYNTVATL (HIV-1 gag p17)Human T-lymphotropic Virus (HTLV)Hayashi, D. et al.(2008). Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-1-associated myelopathy. J Neuroimmunol. 200: 115-124 [PubMedID: 18639344] A*02:01/LLFGYPVYV (HTLV Tax)A*02:01/CLGGLLTMV (CMV LMP2)A*02:01/NLVPMVATV (CMV pp65)A*02:01/SLYNTVATL (HIV gag17)Manuel, SL. et al. (2009). Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatry disease. J. Leukoc. Biol. 86: 86: 1205-1216 [PubMedID: 19656902] A*02:01/LLFGYPVYV (HTLV-1 Tax)Matsuura, E. et al. (2008). Inclusion body myositis associated with human T-lymphotropic virus-type I infection: Eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol. 67: 41-49. [PubMedID: 19656902] A*02:01/LLFGYPVYV (HTLV Tax)A*02:01/GILGFVFTL (Influenza MP)Oliveira, ALA. et al (2009). High frequencies of functionally competent circulating Tax-specific CD8+ T cells in human T lymphotropic virus type 2 (HTLV-2) infection. J Immunol. 183: 2957-2965 [PubMedID: 19657093] A*02:01/LLYGYPVYV (HTLV-2 Tax-2)A*02:01/NLVPMVATV (CMV pp65)A*03:01/ILRGSVAHK (Influenza NP)B*35:01/IPSINVHHY (CMV pp65)InfluenzaAfonso, G., et al. (2010) Critical parameters in blood processing for T-cell assays: Validation on ELISpot and tetramer platforms. Journal of Immunological Methods (in press) A*02:01/GILGFVFTL (Influenza A MP)Avetisyan, G. et al. (2008). Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation. 86:257-263 [PubMedID: 18645488] A*01:01/ILRGSVAHK (Influenza NP)A*02:01/GILGFVFTL (Influenza MP)A*03:01/CTELKLSDY (Inlfuenza NP)Bannard, O. et al. (2009) Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science. 323: 505-509. [PubMedID: 19164749] H-2Db/ASNENMETM (Influenza NP PR8)Bengsch, B. et al.& (2007). Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J. Virology. 81: 945-953. [PubMedID: [17079288] A*02:01/GILGFVFTL (Influenza A MP)Bohana-Kashtan, O. et al (2009). Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J. Immunol. 183: 696-705 [PubMedID: 19535642] A*02:01/GILGFVFTL (Influenza MP)B*07:02/RPPIFIRRL (EBV EBNA-3)Currie, AJ. et al. (2009) Dual Control of Antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: Regulation and counterregulation. J. Immunol. 183: 7898-7908. [PubMedID: 20007574] H-2Kd/IYSTVASSL (Influenza HA)DiNapoli, JM. et al. (2008). Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virology Journal. 5: 105 [PubMedID: 18816384] H-2Kd/TYQRTRALV (Influenza NP)H-2Kd/SYIGSINNI (RSV M2)Fiore, F. et al. (2007). Enhanced ability of dendritic cells to stimulate innate and adaptive immunity upon short-term incubation with zoledronic acid. Blood 110: 921-7. [PubMedID: 17403919] A*02:01/GILGFVFTL (Influenza A MP)Hoelscher, M.A. et al. (2007). New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin. Pharmacol. Ther. 82: 665-71. [PubMedID: 17957181] H-2Kd/IYSTVASSL (Influenza A HA)H-2Kd/TYQRTRALV (Influenza A (PR8) NP)Hoelscher, M.A. et al. (2006). Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. The Lancet 367: 475-481. [PubMedID: 16473124] H-2Kd/IYSTVASSL (Influenza A HA)Liu, Y. et al. (2006). Regulated Expression of Fc{gamma}R in Human Dendritic Cells Controls Cross-Presentation of Antigen-Antibody Complexes. J. Immunol. 177: 8440-8447. [PubMedID:17142741] A*02:01/GILGFVFTL (Influenza A MPLjungman, P. et al. (2008). Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplantation. 42: 637-641. [PubMedID: 18724396] Mostböck, S. et al. (2007). Enhanced levels of costimulation lead to reduced effector/memory CD8+ T cell functionality. J. Immunol. 179: 3524-34. [PubMedID: 17785786] H-2Db/ASNENMDAM (Flu NP68)Mostböck, S. et al. (2008). IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J. Immunol. 180: 5118-5129. [PubMedID: 18354238] H-2Db/ASNENMDAM (Flu NP68)Obermann, S. et al. (2007). Peptide b-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells. Immunology 122: 90-7. [PubMedID: 17472719] A*02:01/GILGFVFTL (Flu MI)A*02:01/SLLMWITQV (NY-ESO-1)Price, GE. et al. (2009). Vaccination focusing immunity of conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine. 27: 6512-6521 [PubMedID: 19729082] H-2Kd/TYQRTRALV (Influenza A NP)Ross, TM. et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLos One. 4: e6032. [PubMedID: 19554101] H-2Kd/IYSTVASSL (Influenza NP)H-2Kd/TYQRTRALV (Infleunza NP)Sawai, T. et al. (2008). Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 124: 155-165. [PubMedID: 18205793] H-2Db/ASNENMDAM (Flu NP)Saxena, A. et al. (2008). Cutting Edge: Multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J. Immunol. 181: 1617-1621 [PubMedID: 18641296] H-2Kd/IYSTVASSL (Influenza A HA)Singh, N. et al. (2008). Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther. 16: 965-71. [PubMedID:18301400] H-2Kd/IYSTVASSL (Influenza HA)Suneetha, PV. et al. (2009). Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. J Immunol. Methods 342: 33-48. [PubMedID: 19135447] A*02:01/GILGFVFTL (Influenza MP)A*02:01/NLVPMVATV (CMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/CINGVCWTV (HCV NS3)Takeuchi, A. et al. (2009). CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymph node. J. Immunol. 183: 4220-4228 [PubMedID: 19752223] H-2Db/ASNENMDAM (Influenza NP)Vogt, A. et al. (2008). Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J. Immunol. 180: 1482-9. [PubMedID:18209043] A*02:01/GILGFVFTL (Influenza MP)Waeckerle-Men, Y. et al. (2005). Dendritic cells generated from patients with androgen independent prostate cancer are not impaired in migration and T cell stimulation. The Prostate 64: 323-331. [PubMedID:15754347 A*02:01/GILGFVFTL (Influenza A MP)Westendorf, A.M. et al. (2006). Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells. Gastroenterology 131: 510-524. [PubMedID: 16890605] H-2Kd/IYSTVASSL (Influenza A HA)Xie, D. and McElhaney, J. (2007). Lower GrB+ CD62Lhigh CD8 TCM effector lymphocyte response to influenza virus in older adults is associated with increased CD28null CD8 T lymphocytes. Mech Ageing Dev. 128: 392-400. [PubMedID:17570460] A*02:01/GILGFVFTL (Flu MP)Zhang, X. et al. (2008). Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Ther. 15: 73-84. [PubMedID: 18084244] H-2Kd/IYSTVASSL (Flu HA)Lymphocytic Choriomeningitis Virus (LCMV)Fousteri, G. et al. (2009). CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes. J. Autoimmunity. 32: 70-77 [PubMedID: 19162441] H-2Db/KAVYNFATC (LCMV gp33)H-2Db/FQPQNGQFI (LCMV NP)Pardo, J. et al. (2008). Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs. Cell Death Differ. 15: 567-579. [PubMedID: 18064039] H-2Db/KAVYNFATC (LMCV gp33)ListeriaBahjat, K. et al. (2009). Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria. PLos Pathogens. 5: e1000568 [PubMedID:19730694] H-2Kb/SIINFEKL (Ovalbumin)Gurung, P. et al. (2009). Chronic ethanol induces inhibition of antigen-specific CD8+ but not CD4+ immunodominant T cell responses following Listeria monocytogenes inoculation. J. Leukoc. Biol.85: 34-43 [PubMedID: 18820175] H-2Kd/GYKDGNEYI (Listeriolysin O)Husseiny, MI. and Hensel, M. (2009) Evaluation of Salmonella live vaccines with chromosomal expression cassettes for translocated fusion proteins. Vaccine 27: 3780-3787 [PubMedID: 19464562] H-2Kd/GYKDGNEYI (Listeriolysin O)Seo, S.K. et al. (2007). Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection. Immunology 123: 90-9. [PubMedID: 17971153] H-2Kd (Listeriolysin O)MalariaRodriguez, A. et al. (2008). Impact of recombinant Ad35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to the liver stage antigen 1 (LSA-1). Infect Immun. 76: 1709-1718. [PubMedID: 18212075] H-2Kd/YYIPHQSSL (LSA Plasmodium falciparum)Tartz, S. et al. (2006). Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria. Infect. Immun. 74: 2277-2285. [PubMedID: 16552058] H-2Kd/SYIPSAEKI (Plasmodium berghei CSP)Tartz, S. et al. (2008). Complete protection against P.berghei malaria upon heterologous prime/boost immunization against circumsporozite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine. 26: 5935-5943. [PubMedID: 18804138] H-2Kd/SYIPSAEKI (CSP)Minor Histocompatibility Antigen (MiHAg)Baldwin, T. et al. (2005). The timing of TCRa expression critically influences T cell development and selection. J Exp Med. 202: 111-121. [PubMedID: 15998791 H-2Db/KCSRNRQYL (miHAg smcy)D'Asaro, M. et al. (2006). Increase of CCR7(-) CD45RA(+) CD8 T cells (T(EMRA)) in chronic graft-versus-host disease. Leukemia 20: 545-547. [PubMedID:16408100] A*02:01/FIDSYICQV (miHAg SMCY)Fan, Y. et al. (2009). Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J. 28: 2812-2824. [PubMedID: 19680229] H-2Db/WMHHNMDLI (miHAg UTY)Eiz-Vesper, B. et al. (2006). Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells. Transfusion 46: 1210-1220. [PubMedID:16836569] Hu, Q. et al. (2009). Bim-mediated Apoptosis in not necessary for thymic negative selection to ubiquitous self-antigens. J. Immunol. 183: 7761-7767. [PubMedID: 19933852] H-2Db/KCSRNRQYL (miAg SMCY)Kwun, J. et al. (2007) Altered distribution of H60 minor H Antigen-specific CD8 T cells and attenuated chronic vasculopathy in minor histocompatibility antigen mismatched heart transplantation in Cxcr3-/- Mouse Recipients. J Immunol. 179: 8016-8025. [PubMedID: 18056341] H-2Kb/SGIVYIHL (H4b)H-2Kb/KAPDNRDTL (H7b)H-2Kb/SSVIGVWYL (H13b)H-2Kb/ILENFPRL (H28)Mycobacterium TuberculosisBegum, D. et al. (2009). Accelerated induction of mycobacterial antigen-specific CD8+ T cells in the Mycobacterium tuberculosis-infected lung by subcutaneous vaccination with Mycobacterium bovis bacille Calmette-Guerin. Immunology. 128: 556-563. [PubMedID: 19930045] H-2Db/GAPINSATAM (Mycobacterium Tuberculosis 32a)Billeskov, R. et al. (2007). Induction of CD8 T Cells against a novel epitope in TB10.4: Correlation with mycobacterial virulence and the presence of a functional region of Difference-1. J. Immunol. 179: 3973-3981 [[PubMedID:17785835] H-2Kb/IMYNYPAM (Mycobacterium tuberculosis M.tb 10.4)Caccamo, N. et al. (2006). Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J. Immunol. 177: 1780-1785. [PubMedID: 16849488] A*02:01/GLPVEYLQV (Mycobacterium bovis antigen 85-A)Hoang, TTKT. et al. (2009). Distinct differences in the expansion and phenotype of TB10-4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. PLoS ONE. 4: e5928 [PubMedID: 19529765] H-2Kb/IMYNYPAM (Mycobacterium tuberculosis M.tb 10.4)Jaron, B. et al. (2008). Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS ONE 3: e2833 [PubMedID: 18665224] H-2Kd/VYAGAMSGL (TB10.3/4:208-28)Radosevic, K. et al. (2007). Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains (H-2d vs. H-2b): CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75: 4105-4115. [[PubMedID:17526747] Respiratory Syncytial Virus (RSV)Beyer, M. et al.(2005). The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res. 6: 70-80. [PubMedID:16011799] H-2Kd/SYIGSINNI (RSV M2)Cyr, SL. et al. (2007). Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine. 25: 5378-5389. [PubMedID: 17561317] H-2Kd/KYKNAVTEL (RSV A strain F protein)DiNapoli, JM. et al. (2008). Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virology Journal. 5: 105 [PubMedID: 18816384] H-2Kd/TYQRTRALV (Influenza NP)H-2Kd/SYIGSINNI (RSV M2)Kochenderfer, J.N. et al. (2006). Synergism between CpG-Containing Oligodeoxynucleotides and IL-2 Causes Dramatic Enhancement of Vaccine-Elicited CD8+ T Cell Responses. J. Immunol. 177: 8860-8873. [PubMedID:17142789] H-2Kd/SYIGSINNI (RSV M2)Pribul, P. et al. (2008). Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J. Virol. 82: 4441-4448. [PubMedID:18287232] H-2Kd/SYIGSINNI (RSV M2)Smit, J.J. et al. (2008). The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE 3(3): e1720. [PubMedID:18320041 H-2Kd/SYIGSINNI (RSV M2)Trypanosoma Cruzide Alencar, BCG. et al. (2009). Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infection & Immunity. 77: 4383-4395. [PubMedID: 1965871] H-2Kb/VNHRFTLV (Trypanosoma cruzi ASP-2)Tzelepis, F. et al. (2008) Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance. J Immunol. 180: 1737-1748. [PubMedID: 18209071] H-2Kb/VNHRFTLV (Trypanosoma cruzi ASP-2)Vaccinia VirusFreyschmidt, E-J. et al. (2007). Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus. J. Allergy Clin. Immunol. 119:671-679. [PubMedID: 17336617] Laouar, A. et al. (2008) Concurrent generation of effector and central memory CD8 T cells during vaccinia virus infection. PLoS one. 3: e4089 [PubMedID: 19116651] H-2Kb/TSYKFESV (vaccinia virus B8R)Luckashenak, N. et al. (2008). Constitutive crosspresentation of tissue antigens by dendritic cells control CD8+ T cell tolerance in vivo. Immunity. 28: 521-532. [PubMedID: 18387832] H-2Kb/SIINFEKL (Ovalbumin)H-2Kb/SSIEFARL (HSV-gpB)H-2Kb/TSYKFESV (vaccinia virus B8R)Oyoshi, MK. et al. (2009). Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. PNAS 106: 14954-14959. [PubMedID: 19706451] H-2Kb/TSYKFESV (vaccibia virus B8R)Rosenthal, R. et al. (2009). Differential responsiveness to IL-2, IL-7 and Il-15 common receptor g chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother. 32: 252-261. [PubMedID: 19242375] A*02:01/NLVPMVATV (CMV pp65)A*02:01/GLCTLVAML (EBV BMLF-1)A*02:01/ELAGIGILTV (MelanA/MART-1)A*02:01/SLSAYIIRV (Vaccinia Virus H3L)A*02:01/KVDDTFYYV (Vaccinia Virus C7L)Samuelsson, C. et al. (2008). Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118: 1776-1784 [PubMedID: 18398511] H-2Kb/TSYKFESV (modified vaccinia virus ankara)OtherBaschuk, N. et al. (2007). Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40 large tumor antigen-specific CTL in BALB/c mice. Cancer Immunol. Immunother. 56: 1625-36. [PubMedID: 17431618] H-2Kb/VVYDFLKL (SV40 tag)Carr, D.J.J. et al. (2006). The lack of RNA-dependent protein kinase enhances susceptibility of mice to genital herpes simplex virus type 2 infection. Immunology 118: 520-526. [PubMedID:16895559] H-2Kb/SSIEFARL (HSV-1 gp B)Claassen, EA. et al. (2007). Identification of a CD4 T cell epitope in the pneumonia virus of mice glycoprotein and characterization of its role in protective immunity. Virology. 368: 17-25. [PubMedID: 17632195] H-2Kd/CYLTDRARI (PVM G)Claassen, E.A. (2005). Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection. J. Immunol. 175: 6597-6604. [PubMedID:16272314] H-2Kd/CYLTDRARI (PVM G)de Beukelaar, JW. et al. (2007) No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol Immunother.56: 1501-1506. [PubMedID: 17597332] A*01:01/ELEQLFSQY (HuD-SCLC)A*01:01/RLDNLLNMAY (HuD-SCLC)A*02:01/SLGYGFVNYI (HuD-SCLC)A*02:01/NLLNMAYGV (HuD-SCLC)A*02:01/QLFGPFGAV (HuD-SCLC)A*02:01/RLGDRVLQV (HuD-SCLC)A*02:01/QYGRIITSRI (HuD-SCLC)Dudek, T. et al. (2008) Disruption of the UL41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology. 372: 165-175 [PubMedID: 18006033] H-2Kb/SSIEFARL (HSV gpB)Duplan, V. et al. (2007). Tracking antigen-specific CD8+ T cells in the rat using MHC class I multimers. J. Immunol. Methods 320: 30-39. [PubMedID: 17223126] First custom Pentamer synthesized for rat MHCFallarino, F. et al. (2006). The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor z chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176: 6752-6761. [PubMedID:16709834] Isa, A. et al. (2005). Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med. 2: e343. (Epub) [PubMedID: 16253012] Jakel, S. et al. (2009). Differential interferon responses enhance viral epitope generation by myocardial immunoproteasomes in murine enterovirus myocarditis. Am. J. Pathol. 175: 510-518. [PubMedID:19590042] H-2Db/FRHNNVTLM (VP2)H-2Kb/TLPAFSTL (P3D)Liu, K. et al. (2006). CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J. Immunol. 176: 3374-3382. [PubMedID:[16517705] H-2Ld/SPSYVYHQF (MuLV env gp70)Luckashenak, N. et al. (2008). Constitutive crosspresentation of tissue antigens by dendritic cells control CD8+ T cell tolerance in vivo. Immunity. 28: 521-532.[PubMedID: 18387832] H-2Kb/SIINFEKL (Ovalbumin)H-2Kb/SSIEFARL (HSV-gpB)H-2Kb/TSYKFESV (vaccinia virus B8R)Matter, M. et al. (2006). Elimination of chronic viral infection by blocking CD27 signaling. J. Exp. Med. 203: 2145-2155. [PubMedID: 16923852] Mazzarella, G. et al (2008). Gliadin activates HLA class-1-restricted CD8+ T cells in celiac disease intestinal mucosa and induces enterocyte apoptosis. Gastroenterology. 134: 1017-1027. [PubMedID: 18395083] A*02:01/QLIPCMDVVL (Gliadin pA2)A*02:01/SLYNTVATL (HIV-1 gag17)Panoskaltsis-Mortari, A. et al. (2008). In situ identification of allospecific B cells using pentamers. Blood 111: 3904-5. [PubMedID:18362221 H-2Kd/GYKDGNEYI (Listeriolysin O)H-2Kd/RRLGRTLLL (Polyoma virus middle T protein)Svensson, A. et al. (2005). Neurokinin 1 receptor signaling affects the local innate immune defense against genital Herpes virus infection. J. Immunol. 175: 6802-6811. [PubMedID:16272337] H-2Kb/SSIEFARL (HSV-1 gp B<)Svensson, A. et al. (2005). Protective immunity to genital herpes simplex virus type 2 infection is mediated by T-bet. J. Immunol. 174: 6266-6273. [PubMedID:15879125] H-2Kb/SSIEFARL (HSV-1 gp B)Takamura, S. et al. (2010) Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8+ T Cells by Rapid Induction of Multiple Inhibitory Receptors. Journal of Immunology 184: 4696-4707 [PubMedID:20351188] H-2Db/CCLCLTVFL (F-MuLV gag 75-83)Verschelde, C. et al. (2006). Overexpression of the antiapoptotic protein A1 promotes the survival of double positive thymocytes awaiting positive selection. Cell Death Differ. 13: 1213-1221. [PubMedID:16294210] Wickham, S. et al. (2005). Chemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitis. J. NeuroImmunol. 162: 51-59. [PubMedID:15833359] H-2Kb/SSIEFARL (HSV-1 gp B)Yang, W. et al. (2007). Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). Int. Immunol. 19: 1083-1093 [PubMedID:17660502] Model AntigenAbdel-Motel, UM. et al. (2009). Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine. 27: 3072-3082. [PubMedID: 19428921] H-2Kb/SIINFEKL (Ovalbumin)Annoni, A. et al. (2009). In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood. 114: 5152-5161. [PubMedID: 19794140] H-2Kd/HYLSTQSAL (eGFP)Arnaboldi, PM. et al. (2009). Suppression of Th1 and Th17, but not Th2, responses in a CD8+ T cell-mediated model of oral tolerance. Mucosal Immunology. 2: 427-438. [PubMedID: 19571798] H-2Kb/SIINFEKL (Ovalbumin)Bahjat, K.S. et al. (2006). Cytosolic Entry Controls CD8 + T cell Potency During Bacterial Infection. Infect. Immun. 74: 6387-6397. [PubMedID: 16954391] H-2Kb/SIINFEKL (Ovalbumin)Bahjat, K. et al. (2009). Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria. PLos Pathogens. 5: e1000568 [PubMedID:19730694] H-2Kb/SIINFEKL (Ovalbumin)Bellone, M. et al. (2010). iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS ONE. 5: e8646. [PubMedID: 20072624] H-2Kb/SIINFEKL (Ovalbumin)Binder, R.et al. (2005). Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nature Immunol. 6: 593-599. [PubMedID: 15864309] H-2Kb/SIINFEKL (Ovalbumin)Bouma, G. et al. (2007). Impaired T cell priming in vivo resulting from dysfunction of WASp-deficient dendritic cells. Blood. 110: 4278-84 [PubMedID:17673604] H-2Kb/SIINFEKL (Ovalbumin)Bourquin, C. et al. (2008). Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol. 181: 2990-2998 [PubMedID: 18713969] H-2Kb/SIINFEKL (Ovalbumin)Bourquin, C. et al. (2007). Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T cell and IgG2a response. Blood 109: 2953-2960. [PubMedID:17132722] H-2Kb/SIINFEKL (Ovalbumin<)Connolly, MK. et al. (2009). In liver fibrosis, dendiritc cells govern hepatic inflammation in mice via TNF-a. J. Clin. Invest. 119: 3213-3225 [PubMedID:19855130] H-2Kb/SIINFEKL (Ovalbumin)Degl'Innocenti, E. et al. (2008). Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+/CD25+ regulatory T cells. Cancer Res. 68: 292-300. [PubMedID: 18172322] H-2Kb/VVYDFLKL (SV40 T antigen)Diebold, SS. et al. (2008). Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Therapy. 16: 359-366 [PubMedID: 19052633] H-2Kb/SIINFEKL (Ovalbumin)Ding, C. et al. (2008) Targeting of antigens to B cells augments antigen-specific T cell responses and breaks immune tolerance to tumor-associated MUC1. Blood 112: 2817-2825 [PubMedID: 18669871] H-2Kb/SIINFEKL (Ovalbumin)Ga, M. et al. (2007). Single CX3CL1-Ig DNA administration enhances T cell priming in vivo. Vaccine 25: 4554-63. [PubMedID:[17493713] H-2Kb/SIINFEKL (Ovalbumin)Ghosh, A. et al. (2008).Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion. J Immunother. 31: 121-131. [PubMedID:18481382] H-2Kb/SIINFEKL (Ovalbumin)Grolleau-Julius, A. et al. (2008). Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res 68: 6341-6349 [PubMedID: 18676859] H-2Kb/SIINFEKL (Ovalbumin)Gutermuth, J. et al. (2009). Self-peptides prolong survival in murine autoimmunity via reduced IL-2/IL-7-mediated STAT5 signaling, CD8 coreceptor, and V{alpha}2 down-regulation. J. Immunol. 183: 3130-3138. [PubMedID: 19675167] H-2Kb/SIINFEKL (Ovalbumin)Harms, JS. et al. (2009) Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella. Journal of Immune Based Therapies and Vaccines. 7: 1 [PubMedID: 19126207] H-2Kd/HYLSTQSAL (eGFP)Hamasaki, T. et al. (2010). Modulation of Gene Expression Related to Toll-Like Receptor Signaling in Dendritic Cells by Poly(g-Glutamic Acid) Nanoparticles. Clinical and Vaccine Immunology 17: 748-276 [PubMedID: 20219877] H-2Kb/SIINFEKL (Ovalbumin)Kim, YH. et al. (2008) Combination therapy with cisplatin and anti-4-1BB synergisic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res. 68: 7264-7269 [PubMedID: 18794112] H-2Kb/SIINFEKL (Ovalbumin)Kim, YH. et al. (2009) Mechanisms involved in synergisitic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol. Cancer Ther. 8: 469-478. [PubMedID:19190115] H-2Kb/SIINFEKL (ovalbumin)Leggat, JA. et al. (2008). Innate responsiveness of CD8 memory T-cell populations nonspecifically inhibits allergic sensitization. J. Allergy Clin. Immunol. 122: 1014-1021. [PubMedID: 18804851] H-2Kb/SIINFEKL (Ovalbumin)Luci, C. et al. (2006). Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the non-toxic B subunit of Cholera toxin. J. Immunol. 176: 2749-2757. [[PubMedID:16493030] H-2Kb/SIINFEKL (Ovalbumin)Luckashenak, N. et al. (2008). Constitutive crosspresentation of tissue antigens by dendritic cells control CD8+ T cell tolerance in vivo. Immunity. 28: 521-532. [PubMedID: 18387832] H-2Kb/SIINFEKL (Ovalbumin)H-2Kb/SSIEFARL (HSV-gpB)H-2Kb/TSYKFESV (vaccinia virus B8R)Martin-Orozco, et al. (2006). Programmed Death (PD) Ligand-1/PD-1 Interaction Is Required for CD8+ T Cell Tolerance to Tissue Antigens. J. Immunol. 177: 8291-8295. [PubMedID:17142723] H-2Kb/SIINFEKL (Ovalbumin)Mascolo, D. et al. (2007). Phage display of a CTL epitope elicits a long-term in vivo cytotoxic response. FEMS Immunol. Med. Microbiol. 50: 59-66. [PubMedID: 17391361] H-2Kb/SIINFEKL (Ovalbumin)H-2Kb/SSYSYSSLMcBurney, WT. et al. (2008). In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine. 26: 4549-4556 [PubMedID: 18585421] H-2Kb/SIINFEKL (Ovalbumin)McIlroy, D. et al. (2009). DNA/Amphiphilic block copolymer nanospheres promote low-dose DNA vaccination. Mol. Ther. 17: 1473-1481 [PubMedID: 19417740] H-2Kb/SIINFEKL (Ovalbumin)Mouries, J. et al. (2008). Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood. 112: 3713-3722 [PubMedID: 18698004] H-2Kb/SIINFEKL (Ovalbumin)Nitcheu-Tefit, J. et al. (2007). Listeriolysin O expressed in a bacterial vaccine suppresses CD4+ CD25high regulatory T cell function in vivo. J. Immunol. 179: 1532-1541. [PubMedID:17641019] H-2Kb/SIINFEKL (Ovalbumin)Noble, A. et al. (2006). Cytokine-induced IL-10-secreting CD8 T cells represent a phenotypically distinct suppressor T-cell lineage. Blood 107: 4475-4483. [PubMedID:16467201] H-2Kb/SIINFEKL (Ovalbumin)Ohnmacht, C. et al. (2009). Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J. Exp. Med. 206: 549-559 [PubMedID: 19237601] H-2Kb/SIINFEKL (Ovalbumin)Pascual, DW. et al. (2008). The absence of lymphoid CD8+ dendritic cell maturation in L-selectin-/- respiratory compartment attenuates antiviral immunity J Immunol. 181: 1345-1356 [PubMedID: 18606689] H-2Kb/SIINFEKL (Ovalbumin)Puaux, A-L et al. (2006) A very rapid and simple assay based on trogocytosis to detect and measure specific T and B cell reactivity by flow cytometry. Eur. J. Immunol. 36: 779-788. [PubMedID:16482513] H-2Kb/SIINFEKL (Ovalbumin)H-2Db/KAVYNFATC (LCMV GP1)Ren, Y. et al. (2006). OVA-specific CD8+ T cells do not express granzyme B during anterior chamber associated immune deviation. Graefes Arch. Clin. Exp. Ophthalmol. 244: 1315-1321. [PubMedID:16538449] H-2Kb/SIINFEKL (Ovalbumin)Rowe, HM. et al. (2009). Expression of vFLIP in a lentiviral vaccine vector activates NF-kB matures dendritic cells and increases CD8+ T-cell responses. J. Virol. 83: 1555-1562 [PubMedID: 19036811] H-2Kb/SIINFEKL (Ovalbumin)Russo, V. et al. (2007). Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J. Clin. Invest. 117: 3087-96. [PubMedID:17885685] H-2Kb/SIINFEKL (Ovalbumin)Sakowicz-Burkiewicz, M. et al. (2008) Protein kinase C-{theta} critically regulates the proliferation and survival of pathogen-specific T cells in murine listeriosis. J. Immunol. 180: 5601-5612. [PubMedID:18390745] H-2Kb/SIINFEKL (Ovalbumin)H-2Db/KAVYNFATC (LMCV gp33)Saveanu, L. et al. (2009). IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science. 325: 213-217. [PubMedID:19498108] H-2Kb/SIINFEKL (Ovalbumin)Steitz, J. et al. (2006). Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Ther. 13: 318-325. [PubMedID:16151477] H-2Kb/SIINFEKL (Ovalbumin)Stoitzner, P. et al. (2008). Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J. Immunol. 180: 1991-8. [PubMedID:18209098] H-2Kb/SIINFEKL (ovalbumin)Terabe, M. et al. (2008). IL-15 expands unconventional CD8aa NK1.1+T cells but not Va14Ja18+ NKT cells. J Immunol. 180: 7276-7286. [PubMedID:18490727 H-2Kb/SIINFEKL (Ovalbumin)Thompson, JM. et al. (2008). Alphavirus replicon particlaes acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine. 26: 4267-4275 [PubMedID: 18585421] H-2Kb/SIINFEKL (Ovalbumin)Tomihara, K. et al. (2010). Antigen-Specific Immunity and Cross-Priming by Epithelial Ovarian Carcinoma-Induced CD11b+Gr-1+ Cells [PubMedID: 20427766] H-2Kb/SIINFEKL (Ovalbumin)Tripp, CH. et al. (2009). Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells. J. Immunol. 182: 7644-7654. [PubMedID:19494288] H-2Kb/SIINFEKL (Ovalbumin)Uto, T. et al. (2009). Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles. Biochem. Biophys. Res. Comm. 379:600-604 [PubMedID: 19121627] H-2Kb/SIINFEKL (Ovalbumin)Wells, JW. et al (2008). Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol. 181: 3422-3431 [PubMedID:18714014] H-2Kb/SIINFEKL (Ovalbumin)H-2Kb/SVYDFFVWL (TRP-2)Wells, JW. et al. (2009). Suppression of allergic airway inflammation and IgE responses by a class I restricted allergen peptide vaccine. Mucosal Immunology 2: 54-62 [PubMedID: 19079334] H-2Kb/SIINFEKL (Ovalbumin)Wysocki, PJ. et al. 2006). Captopril, an Angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin. Cancer Res. 12: 4095-4102. [PubMedID:16818710] H-2Kd/HYLSTQSAL (eGFP)Yasuda, T. et al. (2007). Superior anti-tumor protection and therapeutic efficacy of vaccination with allogenic and semiallogenic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 56: 1025-36. [PubMedID:17131118] H-2Ld/SPSYVYHQF (muLV envgp70)H-2Ld/TPHPARIGL (E. Coli b-galactosidase)Zaini, J. et al. (2007). OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J. Clin. Invest. 117: 3330-8. PubMedID: 17975668] H-2Kb/SIINFEKL (Ovalbumin) |
|||||||||||||||||||||
 |
|